The Goldman Sachs Group Initiates Coverage on Esperion Therapeutics (NASDAQ:ESPR)

Equities research analysts at The Goldman Sachs Group started coverage on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note issued on Wednesday, MarketBeat Ratings reports. The brokerage set a “neutral” rating and a $4.00 price target on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price objective indicates a potential upside of 84.33% from the company’s current price.

Several other equities research analysts have also commented on ESPR. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Thursday, December 12th. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Needham & Company LLC restated a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $8.00 price target for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Esperion Therapeutics currently has a consensus rating of “Hold” and an average price target of $7.30.

Esperion Therapeutics Trading Up 0.5 %

ESPR stock opened at $2.17 on Wednesday. The company’s 50-day moving average price is $2.41 and its 200 day moving average price is $2.22. Esperion Therapeutics has a 52 week low of $1.58 and a 52 week high of $3.94. The company has a market cap of $427.57 million, a P/E ratio of -3.39 and a beta of 1.01.

Hedge Funds Weigh In On Esperion Therapeutics

A number of institutional investors have recently made changes to their positions in ESPR. Wasatch Advisors LP boosted its stake in shares of Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after acquiring an additional 6,483,070 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Esperion Therapeutics by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after purchasing an additional 171,609 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of Esperion Therapeutics by 94.2% during the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after purchasing an additional 2,087,635 shares during the last quarter. State Street Corp grew its holdings in shares of Esperion Therapeutics by 2.7% during the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after buying an additional 99,802 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Esperion Therapeutics by 71.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 295,378 shares during the last quarter. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.